The best indicator for Regeneron Pharmaceuticals (REGN)
We backtested 20 indicators across daily, weekly and hourly charts on real Regeneron Pharmaceuticals (REGN) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Stochastic
On the daily chart, this is the strongest risk-adjusted edge we found for Regeneron Pharmaceuticals (REGN) over ~35.2 years — beating buy-and-hold by 1.8% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Heikin-Ashi Trend | Weekly | 15.0% | 0.51 | -60.9% | 43.4% | 327 | 4.3% |
| 2 | Stochastic ✓ | Daily | 12.0% | 0.48 | -78.1% | 66.3% | 184 | 1.8% |
| 3 | Bollinger Mean-Reversion | Daily | 9.8% | 0.45 | -60.8% | 68.7% | 150 | -0.4% |
| 4 | Holy Grail Confluence | Daily | 10.2% | 0.45 | -66.5% | 75.0% | 60 | 0.0% |
| 5 | Stochastic ✓ | Weekly | 10.6% | 0.44 | -83.6% | 73.7% | 38 | -0.1% |
| 6 | WaveTrend (8/6/4) ✓ | Daily | 9.1% | 0.41 | -72.7% | 65.6% | 131 | -1.1% |
| 7 | Money Flow Index ✓ | Daily | 8.6% | 0.41 | -88.1% | 73.5% | 49 | -1.5% |
| 8 | ADX / DMI | Weekly | 9.0% | 0.4 | -65.3% | 41.3% | 46 | -1.6% |
| 9 | WaveTrend (8/6/4) ✓ | Weekly | 9.0% | 0.4 | -71.7% | 61.5% | 26 | -1.7% |
| 10 | Williams %R ✓ | Daily | 8.1% | 0.39 | -87.0% | 68.4% | 215 | -2.1% |
| 11 | Bollinger Mean-Reversion | Weekly | 7.8% | 0.39 | -55.5% | 66.7% | 24 | -2.8% |
| 12 | EMA 20/50 Cross | Weekly | 7.5% | 0.37 | -81.6% | 35.3% | 17 | -3.2% |
| 13 | CCI ✓ | Weekly | 7.4% | 0.37 | -83.6% | 75.0% | 32 | -3.3% |
| 14 | EMA-10 Trend ✓ | Weekly | 7.6% | 0.36 | -74.3% | 42.3% | 168 | -3.1% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Regeneron Pharmaceuticals (REGN), Stochastic on the daily timeframe gave the best balance of return and risk in our test. It beat buy-and-hold — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.